Anti-Human PD-1 (Camrelizumab)

Anti-Human PD-1 (Camrelizumab)

Product No.: P810

- -
- -
Product No.P810
Clone
SHR-1210
Target
PD-1
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
Anti-PD-1, PDCD1, CD279
Isotype
Human IgG4κ
Applications
ELISA
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Recommended Isotype Controls
Immunogen
Human PD-1
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA,
WB
Additional Applications Reported In Literature ?
FA,
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Camrelizumab activity is directed against human PD-1 (CD274).
Antigen Distribution
PD-1 is expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells and is also retained in the intracellular compartments of regulatory T cells (Tregs).
Background
Programmed cell death 1 (PD-1) is a transmembrane protein in the Ig superfamily 1,2 that acts as an immune checkpoint receptor 3, a T cell inhibitory receptor, plays critical roles in peripheral tolerance induction, autoimmune disease prevention, macrophage phagocytosis, tumor cell glycolysis, and dendritic cell survival 2. PD-1 prevents uncontrolled T cell activity, leading to attenuation of T cell proliferation, cytokine production, and cytolytic activities. Additionally, the PD-1 pathway is a major mechanism of tumor immune evasion, and, as such, PD-1 is a target of cancer immunotherapy 2. Programmed cell death 1 ligand 1 (PD-L1; CD274; B7H1) and programmed cell death 1 ligand 2 (PD-L2; CD273; B7DC) are ligands 1. Camrelizumab is a humanized high-affinity monoclonal antibody developed by Jiangsu Hengrui Medicine Co. Ltd as a cancer immunotherapeutic 4 that is derived from murine hybridoma Mab005 5. Camrelizumab binds to and blocks PD-1 binding to PD-L1 and PD-L2, preventing activation of downstream signalling pathways and restoring immune function 4. Camrelizumab also has off-target binding to the vascular receptor VEGFR2 (KDR), frizzled class receptor 5 (FZD5), and UL16 binding protein 2 (ULBP2) due to activity in the complementarity-determining regions of the v-domains from its Mab005 parent 5.

Antigen Details

Ligand/Receptor
PD-L1, CD274
NCBI Gene Bank ID
UniProt.org
Research Area
Cancer
.
Immuno-Oncology
.
Immunology

References & Citations

1. Matsumoto K, Inoue H, Nakano T, et al. J Immunol. 172(4):2530-2541. 2004.
2. Zhao Y, Harrison DL, Song Y, et al. Cell Rep. 24(2):379-390.e6. 2018.
3. Pardoll DM. Nat Rev Cancer. 12(4):252-264. 2012.
4. Markham A, Keam SJ. Drugs. 79(12):1355-1361. 2019.
5. Finlay WJJ, Coleman JE, Edwards JS, et al. MAbs. 11(1):26-44. 2019.
6. Huang J, Xu B, Mo H, et al. Clin Cancer Res. 24(6):1296-1304. 2018.
7. Huang J, Mo H, Zhang W, et al. Cancer. 125(5):742-749. 2019.
Indirect Elisa Protocol
General Western Blot Protocol
- -
- -

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.